アブストラクト
| Title | 敗血症の治療 |
|---|---|
| Subtitle | 特集 敗血症 - 再考,そして未来へ (II) |
| Authors | 垣内大樹*, 佐々木淳一* |
| Authors (kana) | |
| Organization | *慶應義塾大学医学部救急医学 |
| Journal | 医学と薬学 |
| Volume | 78 |
| Number | 3 |
| Page | 205-212 |
| Year/Month | 2021 / 3 |
| Article | 報告 |
| Publisher | 自然科学社 |
| Abstract | 「はじめに」敗血症の定義や治療は1990年代よりさまざまな変遷を遂げ, 現在の敗血症の定義は2016年に発表された「感染により重篤な臓器障害が引き起こされる状態」(Sepsis-3)となり, その定義の下にSurviving Sepsis Campaign Guideline 2016(SSCG2016)や日本版敗血症診療ガイドライン2016(J-SSCG2016)が作成された. 今般, 2020年9月には2016年以降の4年間に発表されたエビデンス等に基づき, 本邦よりJ-SSCG 2020が世界に先駆けて公開された. 敗血症関連死亡は全世界で年間1,100万人(全世界の死亡者の19.7%に相当)とされ, 本邦でも敗血症推定患者数は人口10万対4,600人と想定されており, common diseaseである. さらに先進国での敗血症の死亡率は18.4〜19.0%, 敗血症性ショックの死亡率は38%と報告されており, いまだ死亡率が高い. 敗血症の診療では早期診断・早期治療が重要であり, Surviving Sepsis CampaignからはHour-1 bundleが提唱されており, J-SSCG2020でも時間軸を意識した診療フローが新しく記載されるようになった. |
| Practice | 医学総合 |
| Keywords | Sepsis, J-SSCG2020, Antimicrobials, Vasopressor, Steroid |
- 全文ダウンロード： 従量制、基本料金制の方共に913円(税込) です。
参考文献
- 1) Singer M, Deutschman CS, Seymour CW, et al: The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315(8):801-810, 2016.
- 2) Rhodes A, Evans LE, Alhazzani W, et al: Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med 45(3):486-552, 2017.
- 3) 西田修,小倉裕司,井上茂亮,他:日本版敗血症診療ガイドライン2016.日救急医会誌 28(Suppl 1):S1-232, 2017.
- 4) 江木盛時,小倉裕司,矢田部智昭,他:日本版敗血症診療ガイドライン2020オンライン早期公開版. doi:10.1002/jja2.S0024.
- 5) Rudd KE, Johnson SC, Agesa KM, et al: Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet 395(10219):200-211, 2020.
残りの23件を表示する
- 6) 厚生労働省:平成29年患者調査(傷病分類編)傷病別年次推移表 敗血症. https://www.mhlw.go.jp/toukei/saikin/hw/kanja/10syoubyo/dl/h29syobyo.pdf
- 7) Tulloch LG, Chan JD, Carlbom DJ, et al: Epidemiology and Microbiology of Sepsis Syndromes in a University-Affiliated Urban Teaching Hospital and Level-1 Trauma and Burn Center. J Intensive Care Med 32(4):264-272, 2017.
- 8) Kaukonen KM, Bailey M, Suzuki S, et al: Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 311(13):1308-1316, 2014.
- 9) Vincent JL, Jones G, David S, et al: Frequency and mortality of septic shock in Europe and North America: a systematic review and meta-analysis. Crit Care 23(1):196, 2019.
- 10) Levy MM, Evans LE, Rhodes A: The Surviving Sepsis Campaign Bundle: 2018 update. Intensive Care Med 44(6):925-928, 2018.
- 11) Seymour CW, Liu VX, Iwashyna TJ, et al: Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315(8):762-774, 2016.
- 12) Redfern OC, Smith GB, Prytherch DR, et al: A Comparison of the Quick Sequential (Sepsis-Related) Organ Failure Assessment Score and the National Early Warning Score in Non-ICU Patients With/Without Infection. Crit Care Med 46(12):1923-1933, 2018.
- 13) Ferrer R, Martin-Loeches I, Phillips G, et al: Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med 42(8):1749-1755, 2014.
- 14) Pruinelli L, Westra BL, Yadav P, et al: Delay Within the 3-Hour Surviving Sepsis Campaign Guideline on Mortality for Patients with Severe Sepsis and Septic Shock. Crit Care Med 46(4):500-505, 2018.
- 15) American College of Emergency Physicians: ACEP Statement on SSC Hour-1 Bundle. https://www.acep.org/by-medical-focus/sepsis/
- 16) Filbin MR, Thorsen JE, Zachary TM, et al: Antibiotic Delays and Feasibility of a 1-Hour-From-Triage Antibiotic Requirement: Analysis of an Emergency Department Sepsis Quality Improvement Database. Ann Emerg Med 75(1):93-99, 2020.
- 17) Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, et al: Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med 42(10):1535-1545, 2016.
- 18) Zhao HY, Gu J, Lyu J, et al: Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study. Chin Med J (Engl) 130(10):1139-1145, 2017.
- 19) Leone M, Bechis C, Baumstarck K, et al: De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Intensive Care Med 40(10):1399-1408, 2014.
- 20) Shehabi Y, Sterba M, Garrett PM, et al: Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. Am J Respir Crit Care Med 190(10):1102-1110, 2014.
- 21) Tigabu BM, Davari M, Kebriaeezadeh A, Mojtahedzadeh M: Fluid volume, fluid balance and patient outcome in severe sepsis and septic shock: A systematic review. J Crit Care 48:153-159, 2018.
- 22) Macdonald SPJ, Keijzers G, Taylor DM, et al: Restricted fluid resuscitation in suspected sepsis associated hypotension (REFRESH): a pilot randomised controlled trial. Intensive Care Med 44(12):2070-2078, 2018.
- 23) Permpikul C, Tongyoo S, Viarasilpa T, et al: Early Use of Norepinephrine in Septic Shock Resuscitation (CENSER). A Randomized Trial. Am J Respir Crit Care Med 199(9):1097-1105, 2019.
- 24) Morelli A, Ertmer C, Westphal M, et al: Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 310(16):1683-1691, 2013.
- 25) Wang Z, Wu Q, Nie X, et al: Combination therapy with milrinone and esmolol for heart protection in patients with severe sepsis: a prospective, randomized trial. Clin Drug Investig 35(11):707-716, 2015.
- 26) Annane D, Renault A, Brun-Buisson C, et al: Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. N Engl J Med 378(9):809-818, 2018.
- 27) Darenberg J, Ihendyane N, Sjolin J, et al: Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 37(3):333-340, 2003.
- 28) Linner A, Darenberg J, Sjolin J, et al: Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis 59(6):851-857, 2014.
